Barclays Capital analyst Adam Feinstein has lowered his price targets for Community Health Systems and AmSurg, saying in both cases that lower patient volumes will keep the lid on any upside the companies will see in the coming quarters. In the case of CHS, Feinstein is counting on cost containment — they were up almost 7 percent in the first half, in line with revenue growth — but has taken a whopping 20 percent off his target for the stock (Ticker: CYH). For AmSurg, his target cut is less extreme, but that may be due to the fact that the surgery center chain (Ticker: AMSG) has been dealing with volume issues for more than a year.